lawrence@swangenomics.com

SWAN

Not Long, Not Short… Just Read

PROTO AXIOM

UNSW SYDNEY

SALUS

investible

KiTuaFund

EGB CAPITAL

PACIFIC CHANNEL

iqt

One Platform, All Genomics, No Compromise

Genomics is entering a much larger applied market

Multiple converging market forces are driving this transition

Public health

Cost growing at 2x GDP

Essential for the shift to preventative medicine; lowest cost, best patient outcomes.

Food Resilience

Rising population, fragile supply chains, biological threats

Essential for resilient agriculture and rapid pathogen detection.

Defense and biosecurity

Essential for surveilling bioweaponry and enabling new defense capabilities.



DNA Sequencing is Entering Its Largest Growth Phase

Today genomics is a compromise

Short Read Sequencing

Reads short fragments of synthetic DNA.

Problem: Misses critical information needed for clinical diagnosis, preventative health and surveillance.



Missing Information

Scalable & Affordable

Long Read Sequencing

Captures long, native DNA for a more complete view

Problem: Complex and data-intensive workflows with high sequencing cost

Complete Information



Not Scalable

Our technology today cannot meet the demands of tomorrow's market.

Solution

At SWAN, we're reimagining genomics for tomorrow

SWAN Sequencing

- ✓ Read length agnostic
- ✓ Native DNA, single molecule, **single read**
- ✓ Accurate, scalable and cheap
- ✓ Faster sample to answer
- ✓ Real time readout
- ✓ Lower CapEx and OpEx
- ✓ Simple and more flexible workflow

One Platform. All Genomics. No Compromise

Forget short or long… just read

Scalable SBS Amplifies the Material - We Amplify the Signal

Sequencing With A Nanoantenna (SWAN)

*Makes molecules **1000x brighter***



Not Long, Not Short... Just Read

SWAN will create the only platform that is agnostic to read length. **One workflow, one instrument, all genomics.**

Native DNA/RNA

Preserves native DNA molecule including clinically-relevant methylation patterns and the **potential for direct RNA** sequencing

Scalable

Simple workflow, robust platform, low cost, scalable throughput

The next era of DNA sequencing

One platform, all genomics, no compromise

	NovaSeq X	ONT PromethION48	PacBio Revio	Roche Axelios	**SWAN***
	Cluster-SBS	Single Molecule Pore	Single Molecule ZMW	Single Molecule Pore	Single Molecule SBS
Read length	Short	Long/Ultra-Long	Long	Short - Mid	**Flexible/Agnostic**
Accuracy	80% Q30+ Q60+ with UMIs	Q20 single pass Q30 Duplex	Q30 HiFi	Q40	**Q30 single pass Q60+ consensus**
Gb per 24 hrs	10 Tb	3 Tb	0.5 Tb	24 Tb	**>20 Tb**
Sample to Data Time	3 days	24 hours	24 hours	2-3 days	**8-24 hours**
Cost per Gb	$2	$5	$8	$2	**<$1**
DNA Modifications	Indirect	yes, native DNA	Yes, native DNA	Indirect	**Yes, native DNA**
Direct RNA	No	Yes	No	No	**Yes**
Library prep	Simple	Simple, but arduous QC	Complex	Complex	**Simple**

**HTP Instrument Configuration*

Team with Proven Platform-Building Experience

Lawrence Lee, PhD

Co-founder & CEO

Co-Inventor of SWAN's breakthrough technology

Expertise: DNA nanotechnology, synthetic biology, molecular self-assembly

Morassa Mohseni, PhD

SVP, Product & Commercial Strategy

Contributed to $1.4B in M&A (Ariosa, Omniome)

Expertise: Genomics product & commercial strategy, NGS platform development

Min Huang, PhD

Co-founder, Director of R&D

Co-Inventor of SWAN's breakthrough technology

Expertise: DNA nanotechnology, synthetic biology, molecular self-assembly

Bill Hyun, PhD

Co-founder & Board

Venture Partner at Genoa VC & Faculty at UCSF

Expertise: Strategic Partnerships, Startup Companies, Investor Relations

Brock Siegel, PhD

Co-founder & Chair

Led Applied Bio to 98% market share & first human genome

Expertise: Global commercialization and operations, corporate infrastructure

Mike Finney, PhD

Advisor & Board

30+ years as CEO, advisor, investor, & board

Expertise: Genomics technology development, Corporate Strategy

15+ Companies Exited | **300+ Products** | **100+ Publications** | **25+ Patents**

We have captured enabling IP

Filing no.	DESCRIPTION	Status	Owner
1	**Core IP: the use of plasmonic nanoantenna for DNA sequencing**	PCT Filed. National phase filing in progress	SWAN
2	**Core IP: for SWAN reagents with maximally enhanced signal to noise**	PCT Filed	SWAN
3	**Core IP: on methods for low cost synthesis of plasmonic nanoantenna**	Provisional filed	SWAN
4	**Enabling IP: for high accuracy, single-molecule, single pass DNA sequencing 1**	Provisional filed	SWAN
5	**Enabling IP: for high accuracy, single-molecule, single pass DNA sequencing 2**	Provisional filed	SWAN
6	**Enabling IP: for high accuracy, single-molecule, single pass DNA sequencing 3**	Provisional filing in progress	SWAN
7	**Enabling IP: for high accuracy, single-molecule, single pass DNA sequencing 4**	Provisional filing in progress	SWAN

Testimonials

The Leaders We've Spoken To Agree

Michael Quail, PhD
Principal Scientific Manager

Wellcome Sanger

"The **low cost** and the variable read length... are **truly unique and compelling**"

Kenna Shaw, PhD
Executive Director

MD Anderson

"We would want to test this tomorrow... **Everything's better,** everything's **faster,** everything's **cheaper**"

Viktor Adalsteinsson, PhD
Director

Broad Institute

"**We could do** more samples and time points... broader, more comprehensive tests would become feasible"

They are ready for tools that go beyond today's limits

Positioned to Become a Global Standard in DNA Sequencing



Instrument
One-time Revenue + Service

Consumables
Recurring Revenue



8% share of $27.5B–$35B 2030E NGS TAM. Mix benchmarked vs. Illumina, ONT & PacBio FY2024 actuals.

$USD

INSTRUMENT PORTFOLIO

Deployable
(real time, on person, surveillance)

Benchtop
(on-site, incl clinical)



High-throughput
(population-scale genomics)

Sustainable high revenue growth driven by sale of **consumable kits**

Advancing from Technology Validation to Platform Readiness

✓ $8M AUD Seed Round - Complete

Idea → Technology Validation

SBS Nanoantenna
During Sequencing





Single Molecule SBS with Nanoantenna
2 BB v1.0 Sequencing Instruments

$35M AUD Series A*

Platform Readiness

Fully Integrated Benchtop Prototype with early external validation

Read Length > 1 Kb (path to 10 Kb) with Q30 Single pass Accuracy



Proprietary catalog of nano-antennae and POC for plug-and-play technology

Generate datasets enabling benchmarking against current platforms

** Strong commitment from insiders*

lawrence@swangenomics.com

Snapshot Summary

SWAN

One Platform, All Genomics, No Compromise

We seek **AUD$35M Series A** funding to execute our next stage of development:

Engineered Platform & KOL (Key Opinion Leader) Readiness